Melanoma Coverage from Every Angle

Published Medical Literature

Synergistic Drug Combinations in Treatment of Uveal Melanoma
Predicting Relapse of Stage III Melanoma Using Circulating Tumor Cells
Does Immunotherapy Offer Survival Advantage in Resected Cutaneous Melanoma?
Vemurafenib Plus Cobimetinib in BRAF -Mutant Melanoma: 5-Year BRIM7 Follow-up
Treatment Alternatives to Systemic Chemotherapy for Metastatic Uveal Melanoma
Rates of Skin Cancer Among Sexual Minorities
Exploring the Role of FGFR3 in Melanoma Growth and Metastasis
Immune-Related Adverse Events and Recurrence-Free Survival in Melanoma
Quality of Life of Melanoma Survivors Treated With Pembrolizumab
Study Identifies Potential Biomarker for Response to Immunotherapy for Melanoma
Does Tumor Mitotic Rate Predict Survival Outcomes in Children With Melanoma?
Is Combined Checkpoint Blockade Effective in Treating Uveal Melanoma?
Melanoma Cell Heterogeneity and Adaptive Dosing Schedules
Trends in U.S. Melanoma Incidence Rates Seem to Differ by Age Group
Does Pathologic Response to Immunotherapy Differ in Australian and European Patients With Melanoma?
Personalized Algorithm to Predict Response to Immunotherapy for Melanoma
Can Gut Microbiota Influence Response to Immunotherapy in Patients With Melanoma?
IMMUNED Trial: Neoadjuvant Immunotherapy for Stage IV Melanoma With No Evidence of Disease
Trends in Incidence of Head and Neck Melanoma in Children, Adolescents, and Young Adults
Plasma Levels of TKL-40 Glycoprotein: Prognostic Biomarker in Melanoma?
Efficacy of Nivolumab in Patients With Advanced Ocular or Mucosal Melanoma
Long-Term Outcomes With Nivolumab Plus Ipilimumab for Melanoma Brain Metastases
Long-Term Phase III Trial Results With Adjuvant Ipilimumab for Advanced Melanoma
Why Do Some Patients With Melanoma Fail to Respond to Immunotherapy?
Is Complete Lymph Node Dissection of Benefit for Some Patients With Melanoma?
New Outcome Measure Posited for Immunotherapy in Advanced Melanoma
‘Man With Machine’ Approach to Diagnosing Skin Cancer Lesions
Size of Excision Margins and Survival Outcomes in Cutaneous Melanomas
Nivolumab for Advanced Melanoma: 5-Year Survival
Dosing Schedule for Neoadjuvant Ipilimumab and Nivolumab in Stage III Melanoma
Conservative vs Aggressive Treatment of Minimally Invasive Nail Melanoma
Does a Family History of Melanoma Increase the Risk of Keratinocyte Cancers?
New Prognostic Tool for Cutaneous Malignant Melanoma
Neoadjuvant Talimogene Laherparepvec Plus Surgery for Melanoma: 1-Year Recurrence-Free Survival
Talimogene Laherparepvec Versus GM-CSF in Unresectable Melanoma
Melanoma Brain Metastases: Can Nivolumab and Ipilimumab Cross the Blood-Brain Barrier?
Does Metastasectomy in Stage IV Melanoma Impact Overall Survival?
Neoadjuvant Dabrafenib Plus Trametinib for Stage III Melanoma
Standardized Total Body Skin Exam: Improved Accuracy and Efficiency?
High-Risk Primary Melanomas: Risk of Recurrence
Long-Term Results With Dabrafenib Plus Trametinib in Metastatic Melanoma
Lifetime Incidence of Brain Metastasis in Elderly Patients With Melanoma
Exploring BRAF Inhibitor Resistance Mechanisms in Melanoma
Cutaneous Toxic Effects and Outcomes in Advanced Melanoma
HDAC8 Activity and Resistance to BRAF Inhibitor Therapy in Melanoma
Comparison of Thin Nodular Primary Versus Superficial Spreading Melanomas
Extremity Nevus Count and Risk of Melanoma
Monitoring Metastatic Melanoma Using FDG PET/CT
Can a Single Dose of PD-1 Inhibitor Before Surgery Predict Outcomes in Melanoma?
Is There an Association Between Skin Cancer and Erectile Dysfunction Medications?
Nivolumab/Ipilimumab in Advanced Melanoma: Comparison of Dosing Regimens
Amelanotic Melanomas Versus Pigmented Melanomas: Risk and Survival
Including Parotidectomy in Neck Dissection for Head and Neck Cutaneous Melanoma
Association of Indoor Tanning and Skin Cancer in Canada
Who Ultimately Benefits From New Therapies in Metastatic Melanoma?
Can Diabetes Medication Prevent Growth of Melanoma Cells?
Talimogene Laherparepvec in Unresectable Locoregional Melanoma
State-by-State Analysis of Melanoma: Predicting Differences in Survival
Immunotherapy for Patients With Melanoma and HIV Infection
5-Year Outcomes With Trametinib in BRAF V600 E/K–Mutant Melanoma
Molecular Profiles Count in Therapeutic Choices for BRAF-Mutant Melanoma
Phase I Study of Anti–PD-1 Antibody in Advanced Melanoma
Potential Strategy for Overcoming Resistance to BRAF Inhibitors in Melanoma
Co-targeting of FGFR Signaling in Metastatic Uveal Melanoma
Study of Combination Immune Checkpoint Blockade in Stage III Melanoma Halted
Long-Term Follow-up Shows Continued Benefit With Dabrafenib Plus Trametinib in Stage III Melanoma
Use of Pembrolizumab for Active Brain Metastases in Patients With Melanoma
Biomarker Monitoring for Personalized Treatment of Patients With Advanced Melanoma
Combination of Epacadostat and Pembrolizumab in Advanced Melanoma
Impact of Tumor Board Conferences on Treatment of Skin Cancer
Stage IV Melanoma, Checkpoint Inhibitors, and Pregnancy
Pembrolizumab-Associated Dermatomyositis in a Patient With Melanoma
Immunotherapy for Stage III Melanoma: Neoadjuvant vs. Adjuvant
Predicting SLN Positivity in Patients With Thin Melanoma
Shedding Light on Two Rare Melanoma Subtypes: Desmoplastic and Spindle Cell
Rate of Pediatric Melanoma in Melanoma-Prone Families
Survival Benefit Reported With Combination Therapy for BRAF-Mutant Melanoma
Genetic Susceptibility in Adolescents and Young Adults With Melanoma
BRAF V600–Mutated Metastatic Melanoma: Factors Affecting Survival
Vitamin D Levels in Patients With High-Risk Resected Melanoma
Are Patients With Chronic Lymphocytic Leukemia at Risk for Melanoma?
Can Patients With Melanoma Benefit From Antigen-Specific Immunotherapeutic?
Predicting Radiocurable Patients With Node-Positive Cutaneous Melanoma
Disruption of Intracellular Cholesterol Transport: Potential Approach to Treating Melanoma
Australian Study Sheds Light on Sunscreen Use and Risk of Melanoma
Radiosurgery Plus Immunotherapy in Patients With Brain Metastases From Melanoma
Responses to Immune Checkpoint Inhibitors in Patients With NRAS-Mutant Melanoma
Is There A Relationship Between Daily Aspirin Therapy and Melanoma Risk?
Can a Predictive Scoring Model Differentiate Subungual Melanoma in Situ From Longitudinal Melanonychia?
Who Does Better on Anti–PD-1 Therapy for Melanoma: Younger or Older Patients?
Concordance, Reproducibility of Melanoma Staging: AJCC 8 Versus AJCC 7
Baseline Tumor Size and Prognosis in Pembrolizumab-Treated Melanoma
Efficacy of Immunotherapy for Melanoma: Does Gender Matter?
Psychological Health and Information Needs of New Patients With Uveal Melanoma
Combined BRAF-MEK Inhibitor Therapy in BRAF-Mutant Melanoma
Is There a Link Between Skin Cancers and Alzheimer’s Disease?
Phase III Results of Adjuvant Vemurafenib in BRAF V600–Mutated Melanoma
Dacarbazine Plus Selumetinib: Phase III Results in Metastatic Uveal Melanoma
Predictor of Response Rates to Anti–PD-1 Therapies Across Cancer Types
Biomarker May Help Distinguish Between Pseudoprogression and True Disease Progression in Metastatic Melanoma
PD-1 Blockade in Advanced Desmoplastic Melanoma
‘Obesity Paradox’ in Men With Metastatic Melanoma
Outcomes When Patients With Melanoma Discontinue Nivolumab/Ipilimumab Combination
Continuation of Immunotherapy Beyond Disease Progression in Advanced Melanoma
Clinical Practice Guideline Update for Sentinel Lymph Node Biopsy in Melanoma
Adjuvant Combination Treatment for Resected Stage III Melanoma
Are Two Monoclonal Antibodies Better Than One in Advanced Melanoma?
Long-Term Survival With Pembrolizumab for Advanced Melanoma
Nivolumab Versus Ipilimumab in Patients With Resected Advanced Melanoma

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.